115 related articles for article (PubMed ID: 32782617)
1. Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Yin L; Qiao G; Li Y; Li B; Bai Y; Feng F
Oncol Lett; 2020 Sep; 20(3):2997-3005. PubMed ID: 32782617
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of RhoA Expression Reverts Enzalutamide Resistance via the p38 MAPK Pathway in Castration-resistant Prostate Cancer.
Chen X; Yin L; Xu H; Rong J; Feng M; Jiang D; Bai Y
Recent Pat Anticancer Drug Discov; 2023; 18(1):92-99. PubMed ID: 35339190
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells.
Wang J; Zeng L; Wu N; Liang Y; Jin J; Fan M; Lai X; Chen ZS; Pan Y; Zeng F; Deng F
Drug Resist Updat; 2023 Sep; 70():100985. PubMed ID: 37423117
[TBL] [Abstract][Full Text] [Related]
4. Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of
Xu W; Liu L; Cui Z; Li M; Ni J; Huang N; Zhang Y; Luo J; Sun L; Sun F
Open Med (Wars); 2023; 18(1):20230715. PubMed ID: 37251536
[TBL] [Abstract][Full Text] [Related]
5. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
[TBL] [Abstract][Full Text] [Related]
6. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions.
Tucci M; Zichi C; Buttigliero C; Vignani F; Scagliotti GV; Di Maio M
Onco Targets Ther; 2018; 11():7353-7368. PubMed ID: 30425524
[TBL] [Abstract][Full Text] [Related]
7. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
8. CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer.
Armstrong CM; Gao AC
J Cell Commun Signal; 2017 Mar; 11(1):89-91. PubMed ID: 28255661
[TBL] [Abstract][Full Text] [Related]
9. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
Colditz J; Rupf B; Maiwald C; Baniahmad A
Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
[TBL] [Abstract][Full Text] [Related]
10. Genetic Suppressor Element 1 (GSE1) Promotes the Oncogenic and Recurrent Phenotypes of Castration-Resistant Prostate Cancer by Targeting Tumor-Associated Calcium Signal Transducer 2 (TACSTD2).
Bamodu OA; Wang YH; Ho CH; Hu SW; Lin CD; Tzou KY; Wu WL; Chen KC; Wu CC
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439112
[TBL] [Abstract][Full Text] [Related]
11. Small interfering RNA targeting N-cadherin regulates cell proliferation and migration in enzalutamide-resistant prostate cancer.
Lu CH; Wu CH; Hsieh PF; Wu CY; Kuo WW; Ou CH; Lin VCH
Oncol Lett; 2022 Mar; 23(3):90. PubMed ID: 35126732
[TBL] [Abstract][Full Text] [Related]
12. Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer.
Wu M; Cui J; Hou H; Li Y; Liu S; Wan L; Zhang L; Huang W; Sun G; Liu J; Jin P; He S; Liu M
Front Pharmacol; 2022; 13():871259. PubMed ID: 35548335
[No Abstract] [Full Text] [Related]
13. shRNA-induced silencing of Ras-related C3 botulinum toxin substrate 1 inhibits the proliferation of colon cancer cells through upregulation of BAD and downregulation of cyclin D1.
Huang YS; Jie N; Zhang YX; Zou KJ; Weng Y
Int J Mol Med; 2018 Mar; 41(3):1397-1408. PubMed ID: 29286138
[TBL] [Abstract][Full Text] [Related]
14. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
15. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
[TBL] [Abstract][Full Text] [Related]
16. Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer.
King CJ; Woodward J; Schwartzman J; Coleman DJ; Lisac R; Wang NJ; Van Hook K; Gao L; Urrutia J; Dane MA; Heiser LM; Alumkal JJ
Oncotarget; 2017 Dec; 8(67):111084-111095. PubMed ID: 29340039
[TBL] [Abstract][Full Text] [Related]
17. Enzalutamide for patients with metastatic castration-resistant prostate cancer.
Ramadan WH; Kabbara WK; Al Basiouni Al Masri HS
Onco Targets Ther; 2015; 8():871-6. PubMed ID: 25945058
[TBL] [Abstract][Full Text] [Related]
18. PRKAR2B promotes prostate cancer metastasis by activating Wnt/β-catenin and inducing epithelial-mesenchymal transition.
Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
J Cell Biochem; 2018 Sep; 119(9):7319-7327. PubMed ID: 29761841
[TBL] [Abstract][Full Text] [Related]
19. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
20. Predictive and targeting value of IGFBP-3 in therapeutically resistant prostate cancer.
Hensley PJ; Cao Z; Pu H; Dicken H; He D; Zhou Z; Wang C; Koochekpour S; Kyprianou N
Am J Clin Exp Urol; 2019; 7(3):188-202. PubMed ID: 31317059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
